High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069071" target="_blank" >RIV/00216224:14110/13:00069071 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/13:#0002067
Result on the web
<a href="http://dx.doi.org/10.1200/JCO.2012.46.4743" target="_blank" >http://dx.doi.org/10.1200/JCO.2012.46.4743</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2012.46.4743" target="_blank" >10.1200/JCO.2012.46.4743</a>
Alternative languages
Result language
angličtina
Original language name
High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
Original language description
Purpose: To assess the treatment outcome benefit of multiagent consolidation in young adults with acute myeloid leukemia (AML) in a prospective, randomized, multicenter trial. Patients and Methods: Between December 2003 and November 2009, 1,179 patients(median age, 48 years; range, 16 to 60 years) with untreated AML were randomly assigned at diagnosis to receive either standard high-dose cytarabine consolidation with three cycles of 18 g/m(2) (3x HD-AraC) or multiagent consolidation with two cycles ofmitoxantrone (30 mg/m(2)) plus cytarabine (12 g/m(2)) and one cycle of amsacrine (500 mg/m(2)) plus cytarabine (10 g/m(2); MAC/MAMAC/MAC). Allogeneic and autologous hematopoietic stem-cell transplantations were performed in a risk-adapted and priority-based manner. Results: After double induction therapy using a 3 + 7 regimen including standard-dose cytarabine and daunorubicin, complete remission was achieved in 65% of patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
31
Issue of the periodical within the volume
17
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
2094-2102
UT code for WoS article
000320104400015
EID of the result in the Scopus database
—